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Tumor associated ﬁbroblasts (TAFs) are considered a microenvironmental element critical for tumor growth and progression.
Experimental studies suggest that their origin could be from mesenchymal stem cells (MSCs) derived from the bone marrow.
However, the role played by TAFs in cirrhosis, hepatocellular carcinoma development, and progression is largely unknown, and in
vitro human models are missing. This paper for the ﬁrst time demonstrates that (1) human neoplastic livers possess a population
of multipotent adult stem cells (MASCs) with properties of TAFs; (2) a population of MASC-derived TAFs is already present in
cirrhotic, not yet neoplastic, livers; (3) MASCs isolated from nonneoplastic and noncirrhotic liver scan acquire a TAF phenotype
when grown in a medium conditioned by tumor cell lines, supporting the notion that TAF could originate from resident primitive
cells (MASCs), possibly through a paracrine mechanism.
1.Introduction
Recently, it has been recognized the existence, in the liver,
of a strict connection linking development, regeneration,
and carcinogenesis [1, 2]. As a consequence, researchers are
trying to dissect the molecular mechanisms regulating liver
homeostasis, the comprehension of which could open the
way to new targeted therapies for liver regeneration, liver
cirrhosis, and primary liver cancers [1, 2].
In this regard, during liver injury, the reparative pro-
cesses take advantage of two principal strategies of defense,
depending on the extent of the damage [1]. While mild
injury is mainly repaired through compensatory hyperplasia
of hepatocytes, severe damage implies the activation of
a liver progenitor cell compartment [2]. In both cases,
other nonparenchymal cells (stellate cells, vascular, and
biliary endothelial cells) proliferate as soon as hepatocytes
start to [2] and cooperate to restore morphofunctional
competent liver tissue. Conversely, chronic liver diseases are
often characterized by an unbalance between epithelial cell
proliferation and stroma remodeling. As a consequence,
the clinical course of chronic liver diseases signiﬁcantly
depends on the progression rate and the extent of ﬁbrosis
[3]. This latter may be considered as an unrestricted
wound healing process, which causes matrix synthesis sec-
ondary to the activation of hepatic stellate cells, ﬁbrob-
lasts, hepatocytes, and biliary epithelial cells. These latter
two are converted to matrix-producing (myo-) ﬁbroblasts
by a process deﬁned as epithelial-mesenchymal transition
[3, 4].2 International Journal of Hepatology
Epidemiologically, chronic wounds and inﬂammatory
states are well-known risk factors for cancer development
and the connection between cirrhosis and liver cancer is
paradigmatic [5, 6]. In this regard, it has been proposed
that tumor stroma can be considered as “normal wound
healing gone awry [7],” able to interact through paracrine
and juxtacrine pathways with the tumor stem cells that
are inﬂuenced by the microenvironment in which they are
endowed [8–12]. Cells of the tumor microenvironment,
therefore, play active roles in determining the malignant
phenotype [12–16].
Amongtheconstituentsofthetumormicroenvironment,
akeyroleintumorprogression,tumorgrowth,angiogenesis,
and metastasis is played by the tumor associated ﬁbroblast
(TAF), also named cancer-associated ﬁbroblasts (CAFs),
[11, 12, 16–18]. TAFs are characterized by the expression
of speciﬁc markers [9, 18–22] and, although their origin
remains controversial, their presence may be essential for the
invasive growth of the tumor, which culminates into a poor
clinical prognosis [12, 18]. Thus, management of stromal
reaction through prevention of the formation of TAFs is a
potentially attractive opportunity for therapy [17].
Regarding liver cancer, although it has been demon-
strated the presence of activated myoﬁbroblasts, possibly
originating from activated hepatic stellate cells [23], the
role played by TAFs in cirrhosis, HCC development, and
progression is largely unknown, and in vitro human models
are missing.
Recently, our group has optimized a method to isolate,
from several human adult tissues, a population of primitive
cells named multipotent adult stem cells (MASCs), charac-
terizedbyamesenchymalimmunophenotype,clonogenicity,
and a wide in vitro diﬀerentiation capacity, being able, inde-
pendently from the tissue of origin, to give rise to multiple
mature cell types of all the three germ layers [24, 25].
In this work, we decided to investigate the possibility to
isolate and characterize MASCs both from neoplastic and
from cirrhotic human liver tissues to test the hypothesis that
liver-resident MASCs could generate TAFs in pathological
conditions such as cirrhosis or liver cancer. Interestingly,
we demonstrated the existence of a population of MASCs
characterized by TAFs characteristics both in human hepa-
tocellular carcinoma and in cirrhotic livers, suggesting that
MASCs with TAF featurescan contributeto the development
of a microenvironment favoring HCC onset. To further
support the hypothesis that MASCs obtained from normal
livers could generate TAFs, when exposed to HCC cells, ﬁrst
we demonstrated that MASCs isolated from nonneoplastic,
non-cirrhotic livers do not possess aberrant growth prop-
erties, then we showed that they can acquire TAFs features
when exposed to speciﬁc inducing conditions, supporting
for the ﬁrst time the notion that TAFs can originate from
resident primitive cells.
2.MaterialsandMethods
Human liver samples were collected by the Surgery Depart-
ment of the Azienda Ospedaliero Universitaria of Udine,
after informed consent was obtained, in accordance with
the Declaration of Helsinki, and with approval by the
Independent Ethics Committee of the University-Hospital of
Udine.
2.1. Tissue Donors. The principal characteristics of tissue
donors are summarized in Table 1. Samples were obtained
from (1) nonneoplastic and noncirrhotic livers discarded
for orthotopic liver transplantation for clinical reasons; the
histological conditions of the livers showed the presence of a
moderate grade of steatosis, mainly microvesicular, without
ﬁbrosis of the portal trees or necrosis of the hepatocytes
(L); (2) cirrhotic livers aﬀected by hepatocellular carcinoma
(HCC); and (3) cirrhotic livers not aﬀected by HCC. In
particular, in HCC livers we obtained samples from two
diﬀerent regions: the neoplastic area (N) and a remote,
cirrhotic, macroscopically nonneoplastic region (C). While
half of each sample was formalin ﬁxed-paraﬃne m b e d d e d
and microscopically evaluated by an expert pathologist, the
other half was utilized for cell isolation.
2.2. MASCs Isolation and Culture. Cells from nonneo-
plastic and noncirrhotic livers were isolated and cultured
as described in [24]. Liver sample fragments obtained
from cirrhotic and neoplastic livers were ﬁrst disaggregated
mechanicallywithscalpelsandthenenzimaticallydissociated
in a 0.25% collagenase type IV solution (Worthington)
in Joklik modiﬁed Eagle’s Medium (Sigma-Aldrich) for 5
minutes at 37◦C. Cell suspension was ﬁltered through a sieve
(BD Falcon) in order to select a population less than 40μm
in diameter.
However 2 ×106 freshly isolated human cells were plated
onto 100mm human ﬁbronectin- (Sigma-Aldrich) coated
dishes (BD Falcon) in an expansion medium previously
described [24]. Once cells reached 70-80% of conﬂuence,
they were detached with 0.25% trypsin-EDTA (Sigma-
Aldrich) and replated at a density of 1-2 × 103/cm2.C e l l s
obtainedfromnonneoplasticnoncirrhoticliverswerenamed
L-MASCs, while those obtained from HCC and cirrhotic
specimens were named N- and C-MASCs, respectively.
2.3. Cell Growth Kinetic. Cells were seeded at a density of
2,000cells/cm2 in expansion medium. Cells were detached
and counted at 1, 2, 5, 9, 12, and 14 days.
2.4. Induction of In Vitro Multilineage Diﬀerentiation. L-, N-
and C-MASCs were diﬀerentiated using the media described
in [24]. At the end of every treatment, cells were ﬁxed either
with 4% buﬀered paraformaldehyde or with a solution of
absolute ethanol: 40% formalin, 9:1.
2.5. Functional Assays. Functionally competent myocytes
were detected by the presence of spontaneous calcium
transients, as evaluated by Fluo-4 imaging (Molecular Probe,
Invitrogen). Fluo-4/DMSO stock solution was diluted to a
ﬁnal concentration of 1–5μMi nab u ﬀered physiological
medium. The nonionic detergent Pluronic, at a ﬁnal con-
centration of 0.02%, was added. Cells were incubated withInternational Journal of Hepatology 3
Table 1: Clinical-pathological characteristics, HCC: hepatocellular
carcinoma, N.D.: not determined, pre-treatment: transarterial
chemoembolization.
No. of HCC patients 15
Age-yr
Mean 58
s.d. 7
No. of male sex (%) 14 (93)
No. of infection (%) 14 (93)
No. of HCV (%) 8 (53)
No. of HBV (%) 5 (33)
No. of HBV + HDV (%) 1 (7)
No. of alcohol use (%) 1 (7)
No. of Pretreatment (%) 13 (87)
Surgery
No. of OLTx (%) 13 (87)
No. of Resection (%) 2 (13)
HCC histopathological grade
No. of G1 (%) 0( 0 )
No. of G2 (%) 7 (47)
No. of G3 (%) 5 (33)
No. of G4 (%) 2 (13)
N o .o fn o td e ﬁ n e d( % ) 1( 7 )
No. of cirrhotic but nonneoplastic livers 3
Age-yr
Mean 58
s.d. 3
No. of male sex (%) 100
No. of infection (%) 0 (0)
No. of HCV (%) 0 (0)
No. of HBV (%) 1 (33)
No. of HBV + HDV(%) 0 (0)
No. of alcohol use (%) 2 (67)
No. of normal livers 5
Age-yr
Mean n.d.
s.d. n.d.
No. of male sex (%) n.d.
Fluo-4 solution at 37◦C and, after 20 minutes, washed in
indicator-free medium. Image acquisitions were performed
using a Leica DMI 6000B inverted microscope. Images
were acquired at a 400x magniﬁcation (HCX PL Fluotar
objective), collecting one image in both Fluo-4 and phase
contrast channels every 5.6 seconds for a period of 90
seconds.
Active calcium deposition sites were identiﬁed by tetra-
cycline (Sigma-Aldrich) incorporation into osteogenic areas
of osteogenic diﬀerentiating cultures, as described in [24].
The active uptake of acetylated low-density lipoprotein
(LDL), the presence of glycogen by periodic acid Shiﬀ (PAS)
staining, and PAS after diastase digestion were used as
markers of hepatocyte function. To test the in vivo uptake
of DiI-labeled acetylated LDL (Molecular Probes), cells were
incubated for 4 hours at 37◦ with 15μg/mL acetylated LDL
and cell ﬂuorescence was analyzed by Leica DMI 6000B
microscope.ForPASstainingsampleswereﬁxedinasolution
of absolute ethanol: 40% formalin 9:1 for 4 minutes,
incubated in 1% periodic acid, and then incubated with
Schiﬀ’s reagent for 30 minutes in darkness and counter-
stained with hematoxylin for 10 minutes. Diastase digestion
was performed by treating section with 1μg/mL preheated
diastase solution (Sigma-Aldrich) at 37◦Cf o r1 5m i n u t e s .
2.6. Soft Agar Assay. To evaluate the ability of L-, N-, and C-
MASCs to grow in an anchorage-independent way, 50,000
cells were plated in a 0.25% soft agar solution in 35mm
plates containing a basal layer of 1% agarose; colonies with
a diameter greater than 100 microns were counted after
4 weeks under a phase contrast microscope (Leica DMI
6000B). For the comparison of L-MASCs cultured in normal
medium and in semiconditioned medium obtained from
HepG2 [26] and HuH7 [27] cell lines, colony formation was
analyzed 2 weeks after seeding. For this purpose, a series
of optical sections, obtained by scanning along the z-axis:
the ﬁeld of interest, were acquired at a 100x magniﬁcation,
using the Leica DMI-6000B setup. Once obtained the sum
image, the number of colonies with a diameter greater than
60microns was quantiﬁed. For each replicate, a volume of
500μm3 was sampled.
2.7. Conditioning of L-MASCs with Semiconditioned Medium
(CM) from HepG2 and HuH7. The HCC cell lines HepG2
[26] and HuH7 [27] were used. One day after seeding into
T75 ﬂasks (2 × 106 cells), HepG2 and HuH7 were washed
twice with serum-free HBSS (Sigma-Aldrich), and then
incubated for 24 hours with serum-free MASCs proliferation
medium (15mL/T75, Sigma-Aldrich). Medium was then
collected, ﬁltered through a 0.22μm ﬁlter (Millipore), and
kept at +4◦C. Serum-free MASCs proliferation medium
incubated for 24 hours in cell culture ﬂasks without cells was
used as control.
For conditioning experiments, conditioned media obt-
ained from HepG2, HuH7 and empty ﬂask, were diluted
1:1 with MASCs proliferation medium in order to obtain
HepG2-CM, HuH7-CM and non-CM, respectively.
However L-MASCs (n = 3) were cultured in HuH7-,
HepG2- and non-CM for 3 passages (≈12 population dou-
blings) and ﬁnally analyzed in terms of population doubling
time, surface immunophenotype, pluripotent-state speciﬁc
transcription factor expression and assayed in migration
and soft-agar assays. All experiments were performed in
triplicate.
2.8. Scratch Assay. In order to evaluate in vitro cell migration
of L-MASCs conditioned, or not, by HepG2 and Huh7, a
scratch assay was performed [28]. In 33mm plate at high
conﬂuence,scratcheswerecreatedutilizing200μLtips.Phase
contrast images of the scratches were acquired at 3-hour
intervals, until their complete closing, utilizing Leica DMI
6000B. Images were then compared and quantiﬁed by Image
J in order to calculate the rate of cell migration. The mean4 International Journal of Hepatology
scratch width did not diﬀer signiﬁcantly in the three culture
conditions being of 553 ± 51μm, 555 ± 131μm, and 515 ±
72μm in non-CM, HepG2-CM, and Huh7-CM, respectively
(P>. 05).
2.9. Reverse Transcriptase PCR Analysis. Total RNA was
extracted from nonconﬂuent cultures of N- and C-MASCs
at P3 or L-MASCs cultured in non-CM, HepG2-CM,
and Huh7-CM using the TRIzol Reagent (Invitrogen).
After treatment with DNase I (Ambion), ﬁrst strand
cDNA synthesis was performed with 1μg total RNA using
random hexanucleotides and MMLV reverse transcriptase
(Invitrogen). PCR ampliﬁcation was carried out in a ﬁnal
volume of 50μL, using 80–150ng cDNA, 10mM Tris-HCl
pH 9.0, 1.5mM MgCl2, 0.2mM dNTPs, 25pmol of each
primer, and 2U Taq I polymerase (Amersham). The PCR
conditions were as follows: 94◦Cf o r2m i n u t e s ;4 0c y c l e sa t
95◦C for 30 seconds, 61◦C for 60 seconds. and 72◦Cf o r6 0
seconds. The optimal conditions and the number of cycles
weredeterminedtoallowampliﬁcationofsampleswithinthe
linearphaseofthePCR.Thereactionproductswereanalyzed
on 3% agarose gels. Primer pairs and product length were
the following: OCT4 reference sequence ENST00000259915
primer FW 5 CGAAAGAGAAAGCGAACCAGTAT3  and
primer RW 5 CGAGAGGATTTTGAGGCTGCT3 (product
lenght 216bp); SOX2 (SRY-box2) reference sequence ENST-
00000325404 primer FW 5 ATGGGTTCGGTGGTCA-
AGT3  and primer RW 5 CCTGTGGTTACCTCTTCC-
TCC3  (product length 60bp); NANOG reference sequence
ENST00000229307 primer FW 5 ATGCCTCACACGGA-
GACTGT3  andprimerRW5 TGCTTATTCAGGACAGCC-
CT3  (product length 66bp); GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) reference sequence ENST000002-
29239 primer FW 5 ACCCACTCCTCCACCTTTGACG3 
and primer RW 5 AGCAAGAGCACAAGAGGAAGAG-
AGA3  (product length 187bp); ACTA2 (actin, α2, smooth
muscle) reference sequence ENSG00000107796 primer FW
5 CTGTTCCAGCCATCCTTCAT3  andprimerRW5 ACA-
GGAATACGATGAAGCCG3  (product lengh 316pb);
THSBS1 (Thrombospondin1) reference sequence ENSG000-
00137801 primer FW 5 TCAGGACCCATCTATGAT-
AAAACCTA3  primer RW 5 GAAATGGTGTTCTTCTCT-
GA3  (product lengh 85pb); FAP (ﬁbroblast activation pro-
tein) reference sequence ENSG0000078098, primer FW 5 A-
TCTATGACCTTAGCAATGGAGAATTTGT3  and primer
RW 5 GTTGGGAGTAAATTAGCATATGTCTATCAA-
AAC3  (product lengh 171pb); FSP1 (S100A4) reference
sequence ENSG00000196154, primer FW 5 TCTTTCTTG-
GTTTGATCCTG3  and primer RW 5 TTCAGACACGTG-
CTTGATGC3  (product lengh 450pb).
2.10. Flow-Cytometry. Proliferating cells were detached with
0.25%trypsin-EDTA(Sigma-Aldrich)and,aftera20-minute
recovery phase, were incubated with either properly con-
jugated primary antibodies: CD13, CD29, CD49a, CD49b,
CD49d, CD90, CD73, CD44, CD59, CD45, HLA-DR,
CD117, CD271, CD34, (BD Biosciences), CD105, CD66e
(Serotech), CD133 (Miltenyi Biotec), E-cadherin (Santa
Cruz Biotechnology), ABCG-2 (Chemicon International),
or with an unconjugated primary antibody: N-cadherin
(Sigma-Aldrich). Unconjugated antibody was revealed using
PE- or FITC-conjugated secondary antibodies (DakoCy-
tomation). Properly conjugated isotype-matched antibodies
were used as a negative control. The analysis was performed
either by FACS-Calibur (BD Biosciences) or by CyAn (Dako
Cytomation).
2.11. Immunoﬂuorescence and Histochemistry. Cells cultured
either in expansion or in diﬀerentiation medium were ﬁxed
in 4% buﬀered paraformaldehyde for 20 minutes at room
temperature (RT). For intracellular stainings, ﬁxed cells were
permeabilized for 8 minutes at RT, with 0.1% Triton X-100
(Sigma-Aldrich) before exposing them to primary antibod-
ies. Primary antibody incubation was performed over night
at 4◦C using the following dilutions: Oct-4 (Abcam, 1:150);
Sox-2 (Chemicon, 1:150); Nanog (Abcam, 1:150); Cytok-
eratins 7, 8, 18, 19 (Biogenex, 1:20); β3-tubulin (Abcam,
1:1000); Smooth Muscle Actin (Dako, 1:50); Connexin 43
(Santa Cruz, 1:40); α-Sarcomeric Actin (Sigma, 1:100);
Osteocalcin (Abcam, 1:100); Gata4 (Santa Cruz, 1:100).
For the following antibodies the incubation was performed
one hour at room temperature: Vimentin (Dako 1:500),
Desmin (Dako 1:200), Tenascin-C (Novocastra 1:200),
and VEGF (Neomarkers 1:100). To detect primary anti-
bodies, A488 and A555 dyes labeled secondary antibodies,
diluted 1:800, were employed (Molecular Probe, Invitro-
gen). Finally, 0.1μg/mL DAPI (Sigma) was used to identify
nuclei. Vectashield (Vector) was used as mounting medium.
Alcyan blue staining was performed in cells ﬁxed in a
solution of absolute ethanol: 40% formalin (9:1). After 1
minute of incubation in Alcyan blue at pH 1.0, cells were
washed in HCl 0.1N and counterstained with nuclear-fast
Red.
von Kossa stain was performed in 4% paraformaldehyde
ﬁxed cells, treated with 5% silver nitrate solution in front
of a 60-watt lamp for 1 hour, and incubated in 5% sodium
thiosulphate. Cells were counterstained with nuclear-fast
Red.
ConfocalimageacquisitionwascarriedoutbyaConfocal
Laser Microscope (Leica TCS-SP2, Leica Microsystems)
utilizing either a 63x oil immersion objective (numerical
aperture: 1.40) or a 40x oil immersion objective (numerical
aperture: 1.25). Epiﬂuorescence and phase contrast images
were obtained utilizing a live cell imaging dedicated system
consisting of a Leica DMI 6000B microscope connected to
a Leica DFC350FX camera (Leica Microsystems, Wetzlar,
Germany). Also, 10x (numerical aperture: 0.25), 40x oil
immersion (numerical aperture: 1.25), and 63x oil immer-
sion (numerical aperture: 1.40) objectives were employed for
this purpose. Bright ﬁeld images were captured utilizing a
Leica DMD108 microscope (Leica Microsystems). Moreover,
10x (numerical aperture: 0.40), 20x (numerical aperture:
0.70), and 40x (numerical aperture: 0.95) objectives were
employed. Adobe Photoshop software was utilized to com-
pose, overlay the images and adjust the contrast (Adobe,
USA).International Journal of Hepatology 5
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Figure 1: (a–d) Phase contrast images of C-MASCs (a, b) and N-MASCs (c, d) in primary culture (a–c) and at the third passage in culture
(b, d). (e) FACS analysis of N-MASCs. Representative ﬂow cytometry histograms of multipotent cell populations. Plots show isotype control
IgG-staining proﬁle (green histogram) versus speciﬁc antibody staining (red histogram).
2.12. Statistics. Two-tailed unpaired-Student t-test and one-
way Anova followed by Bonferroni posttest were utilized to
compare means between two or more groups, respectively
(Prism, version 4.0c). Results are expressed as mean ± SD.
P values less than .05 were considered signiﬁcant.
3. Results
3.1. Multipotent Adult Stem Cells (MASCs) Can Be Obtained
from Neoplastic and Cirrhotic Livers.. I no r d e rt oe s t a b l i s h
whether human cirrhotic livers possess a population of
multipotent adult stem cells (hMASCs), we applied the
method, previously optimized to isolate hMASCs from non-
neoplastic, noncirrhotic livers [24], to n = 15 livers aﬀected
by HCC. Cell lines were obtained both from HCC areas (N)
and from cirrhotic areas distant from HCC (C), which were
macroscopically and microscopically devoid of neoplastic
foci. We named the cell lines N-MASCs and C-MASCs,
respectively. MASCs were also isolated from n = 3s pe c i m e n s
obtained from cirrhotic livers not aﬀected by HCC. As
a control, we utilized n = 5 cell lines obtained from
nonneoplastic, noncirrhotic controls [24] (L-MASCs). The
clinical features of tissue donors analyzed in this study are
summarized in Table 1.6 International Journal of Hepatology
Table 2: Surface immunophenotype of N-, C-, and L-MASCs. Bonferroni post test: ∗P<0.05 C- versus L-MASCs; ∗∗P<0.05 N- versus
L-MASCs.
MASCs P
NCL
CD49b 99.3 ± 1.6 98.4 ± 4.1 84 ± 14 0,0008∗,∗∗
CD13 98.6 ± 2.8 97.8 ± 5.4 97 ± 7n . s .
CD73 97 ± 5.7 98.3 ± 2.9 93 ± 10 n.s.
CD44 90 ± 21.84 92.2 ± 14.5 91 ± 17 n.s.
CD90 90.6 ± 16.4 92.2 ± 19.5 79 ± 20 n.s.
CD59 89.2 ± 23.8 98.2 ± 4.1 82 ± 9n . s .
CD29 88.5 ± 15.4 91.1 ± 19.4 79 ± 15 n.s.
CD49a 86 ± 33.3 89 ± 10.3 70 ± 9n . s .
CD105 84.6 ± 12.9 86.3 ± 21.5 75 ± 16 n.s.
CD49d 54.9 ± 43.7 46.2 ± 31.6 98 ± 2 0.008∗
E-cadherin 4.39 ± 7.5 3.75 ± 9n . d .
CD10 37.7 ± 28.8 31.1 ± 33.4 8.2 ± 10.9 n.s.
N-cadherin 2.56 ± 5.3 2.15 ± 5.1 n.d.
CD66e 0.41 ± 0.58 0.24 ± 0.51 1.4 ± 1.7 n.s.
CD271 0.22 ± 0.20 0.39 ± 0.65 0.52 ± 0.16 n.s.
CD45 0.19 ± 0.26 0.16 ± 0.35 0.05 ± 0.04 n.s.
ABCG2 0.18 ± 0.10 0.24 ± 0.2 0.21 ± 0.12 n.s.
CD117 0.17 ± 0.23 0.11 ± 0.15 0.03 ± 0.05 n.s.
CD133 0.17 ± 0.19 0.23 ± 0.27 0.18 ± 0.24 n.s.
CD34 0.11 ± 0.10 0.10 ± 0.18 0.03 ± 0.05 n.s.
Inlinewiththeepidemiologicaldata,mostofthepatients
were males (93%). All the patients but 1 were aﬀected by a
chronic viral hepatopathy and 87% underwent transarterial
chemoembolization (TACE) before surgery. Surgical treat-
ment consisted in orthotopic liver transplantation in 87% of
cases. About half of neoplasias were at low grade (G1 and
G2).
After 15–20 days from the primary culture, polymorphic
colonies were detected in about 60% and 80% of the N and
C samples, respectively (Figures 1(a)–1(d)). As previously
described, MASCs were obtained with a 100% eﬃciency
from nonneoplastic, noncirrhotic livers. Diﬀerences in the
isolation method (digestion in perfusion versus mechanical-
enzymatic digestion), in thecomposition of thetissueand/or
in the frequency of cells able to grow in culture can explain
the lower eﬃciency of the method in isolating MASCs from
cirrhotic samples. TACE, performed before surgery, could
also have interfered with the lower eﬃciency in isolating
MASCs, especially from the neoplastic region.
After three to four passages in expansion medium,
MASCs displayed a homogeneous, ﬁbroblast-like morphol-
ogy, independently from the tissue of origin (Figures 1(b)–
1(d)). With respect to L-MASCs, C- and N-MASCs were
characterized by a signiﬁcantly longer population doubling
time (27 ± 2, 49 ± 7, and 58 ± 9h o u r s ,r e s p . ;P<. 05
versusL-MASCs).However,despitethediﬀerencesingrowth
kinetic, N-, C-, and L-MASCs behaved as ﬁnite cell lines able
to proliferate for more than 40 population doublings before
reaching cell senescence and growth arrest.
3.2. Multipotent Adult Stem Cells (MASCs) Obtained Either
from Neoplastic or Cirrhotic Livers Possess Stem Cell Features
and Aberrant Growth Properties. M A S C sw e r es t u d i e di n
terms of surface immunophenotype, expression of pluripo-
tent state-speciﬁc transcription factors, and multipotency.
Considering thesurfaceimmunophenotype, asevaluated
by ﬂow-cytometry, N-, C-, and L-MASCs shared a similar
mesenchymal immunophenotype (Figure 1(e) and Table 2).
Interestingly, while N- and C-MASCs did not diﬀer in the
expression of any of the tested markers, some diﬀerences
were seen between these latter and L-MASCs (Table 2).
Speciﬁcally, L-MASCs, with respect to N- and C-MASCs,
were characterized by a lower expression of α(2)-integrin
(CD49b) and by a higher expression of α(4)-integrin
(CD49d) (Table 2).
The role of integrins in tumor growth and metastasis
is well established [29]. Interestingly, α(2)-integrin has
been described to play a crucial role in hepatocarcinoma
cell invasion and metastasis [30], while a transcriptional
repression of the integrin α4 gene caused by aberrant DNA
methylation has been demonstrated in gastric cancer and
cholangiocarcinoma [31].
Regarding the expression of Oct-4, Nanog, and Sox-2,
transcription factors considered to be crucial for the mainte-
nance of embryonic stem cell self-renewal and pluripotency
[32],N-,C-,andL-MASCswereshowntoexpressthemboth
at mRNA and protein level (Figures 2(a)–2(h)).
In order to assess multipotency, N- and C-MASCs were
inducedtodiﬀerentiateintomultiple,maturecelltypesoftheInternational Journal of Hepatology 7
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Figure 2:Pluripotentstate-speciﬁctranscriptionfactorexpression.(a)RepresentativeRT-PCRanalysisofOct-4,Sox-2,Nanog,andGAPDH
mRNA transcripts in N-MASCs. The right lane of each gel is the negative control (H2O). (b–g) Oct-4 (green ﬂuorescence; (b–c)), nanog
(red ﬂuorescence; (d, e)), and sox-2 expression (yellow ﬂuorescence; and (f, g)) in the nuclei of C-MASCs. Nuclei are depicted by the blue
ﬂuorescence of DAPI staining (c, e, g). (h) Quantiﬁcation of pluripotent state-speciﬁc transcription factor expression. Data are presented as
mean ± standard deviation.
three germ layers and tested for the acquisition of functional
as well as molecular features of diﬀerentiation [24].
Cells exposed for three weeks to EGF and b-FGF
displayed a morphological change, even if at lower extent
with respect to L-MASCs. The cells became positive for
β3-tubulin (20 ± 12%), arrayed in ﬁlaments and bundles
(Figure 3(a)).
Cells cultured in an osteogenic medium became positive
both to von Kossa and Alcyan blue stainings, speciﬁc for
the diﬀerentiation toward bone and cartilage, respectively
(Figure 3(b) and 3(c)). Moreover, when cultured in the
presenceoftetracycline,acalciumchelatoroftenusedtolabel
the mineralizing front of forming bone, N- and C-MASCs
were characterized by the gradual deposition of tetracycline-
labeled material, indicating that the newly formed matrix
was also mineralized (Figure 3(d)), and expressed osteocal-
cin (Figure 3(e)). When cultured in a myogenic medium,
a fraction of cells (<10%), expressed smooth-muscle actin
(SMA) (Figure 3(f)), while almost all cells showed positivity
for α-sarcomeric actin (ASA) (Figure 3(g)). The presence of
functionalcompetentreceptorsinvolvedincalciumhandling
was demonstrated by spontaneous intracellular calcium
transients, as displayed by Fluo-4 assays (Supplementary
movie 1 available online at doi: 10.1155/2012/120925).
Cells diﬀerentiated into hepatocytes became positive
for the nuclear transcription factor GATA-4 (Figure 3(h)),
became polygonal, and stained positive for cytokeratins 8–
18-19 (Figure 3(i)). Functionally, cells acquired the abilities
to actively up take acetylated LDL (Figure 3(j)) and to store
glycogen, as demonstrated by PAS staining (Figure 3(k)).
Altogether, the accumulated evidences show that, simi-
larly to what has already been demonstrated for the MASCs
obtained from nonneoplastic and noncirrhotic livers [24],
MASCs obtained from neoplastic and cirrhotic samples are
characterized by a stem cell phenotype and by a wide in vitro
multipotency.However,withrespecttoL-MASCs,N-andC-
MASCs displayed an impaired plasticity, especially toward a
neurogenic fate.
Despite some similarities, the growth properties of N-
and C-MASCs were signiﬁcantly diﬀerent from L-MASCs.
Table 3: Quantiﬁcation of the changes in the expression of speciﬁc
markers in L-MASCs cultured in the presence of non-CM, HepG2-
CM and HuH7-CM. Data are expressed as mean ± standard
deviation. Neg = no expression.
No-CM HepG2-CM HuH7-CM
Vimentin 99 ± 1% 97 ± 3% 97 ± 3%
Nestin 2 ± 1% 15 ± 15% 30 ± 5
Cytokeratins Neg Neg Neg
Desmin Neg 38 ± 5% 85 ± 10%
Smooth muscle actin Neg 7 ± 8% 11 ± 6%
Tenascin-C 10 ± 2% 95 ± 3% 98 ± 2%
VEGF 4 ± 3% 70 ± 21% 85 ± 15%
Speciﬁcally, all MASCs derived from neoplastic and cirrhotic
livers, but not those from nonneoplastic and noncirrhotic
livers, developed colonies in soft agar (Figures 4(a)–4(c)),
a property shared by tumorigenic cells and TAFs [33]. The
ability to grow in soft agar was independent from the
presence of cancer, since C-MASCs obtained from cirrhotic
but nonneoplastic livers (n = 3) were able to grow in soft
agar too (data not shown).
3.3. MASCs Obtained from Normal Liver Can Acquire Abnor-
mal Growth Properties in the Presence of Neoplastic Cell Lines..
InordertoestablishwhetherL-MASCsexposedtoamedium
conditioned by tumor cell lines (TCM) could acquire a
TAF phenotype, we cultured L-MASCs (n = 3) for three
passagesinamediumconditionedbyHuH7[27]andHepG2
[26], two hepatocellular carcinoma cell lines. At the end of
the treatment, L-MASCs were assessed in terms of growth
kinetics, cell surface phenotype, pluripotent-state-speciﬁc
transcription factor, and TAF-speciﬁc marker expression,
migration ability, and adhesion-independent growth.
The population doubling time of L-MASCs did not
signiﬁcantly change after the exposure of cells to TCM, being
of 18 ± 3, 18.5 ± 2, and 16.5 ± 2 hours in non-CM, in
HepG2-CM, and in Huh7-CM, respectively (P>0.05).International Journal of Hepatology 9
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Figure 3: Multipotency of MASCs obtained from neoplastic livers. A neuroectodermic diﬀerentiation: N-MASCs (a) in neurogenic medium
acquired the expression of β3-tubulin (green ﬂuorescence). (b–e) Osteogenic diﬀerentiation: N-MASCs in osteogenic medium display
positivity for von Kossa (b) and Alcyan blue (c) cytochemistry reactions, were able to incorporate tetracycline in sites of calciﬁcation when
excited with a UV laser (red ﬂuorescence, (d)) and presented osteocalcin deposits (green ﬂuorescence, (e)). (f, g) Myocyte diﬀerentiation:
a low fraction of N-MASCs in diﬀerentiation medium express the myocyte-speciﬁc ﬁlament SMA (green ﬂuorescence, (f)), while the large
part of the cells expresses α-sarcomeric actin in the cytoplasm (red ﬂuorescence, (g)). (h–k) Endodermic diﬀerentiation: cells cultured for
one week in a medium added with HGF and FGF-4 became positive for GATA-4 (yellow ﬂuorescence, (h)). Cells cultured for three weeks in
the same medium became positive for cytokeratins 8–18-19 (green ﬂuorescence, (i)) were able to actively uptake DiI-labeled acetylated LDL
(red ﬂuorescence overlaid on a phase contrast image, (j)) and presented diastase-resistant glycogen granules, as revealed by PAS reaction
(purple stain, (k)). In the ﬂuorescence pictures, nuclei are depicted by the blue ﬂuorescence of DAPI staining.
Similarly, culture conditions did not signiﬁcantly change
either the surface immunophenotype or the expression of
Oct-4 and Nanog (data not shown).
Conversely, L-MASCs cultured in the presence of
HepG2-CM or Huh7-CM, started to express a signiﬁcant
increased amount of TAF-speciﬁc markers such as de-
smin, smooth muscle actin, tenascin C and VEGF (Fig-
ures 5(a)–5(u), Table 3), ﬁbroblast-speciﬁc protein (FSP),
thrombospondin-1 (THBS1), and ﬁbroblast activating pro-
tein (FAP) (Figure 5(v)).
Importantly, cell lines grown in the presence of either
Huh7- or HepG2-CM displayed an at least 10-fold increased
ability to grow in anchorage-independent conditions (Fig-
ures 6(a)–6(d)), while no signiﬁcant diﬀerences in the mean
colony size were seen among the three diﬀerent culture con-
ditions.10 International Journal of Hepatology
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Figure 4: Anchorage-independent growth. Representative colonies of N-MASCs developed in soft agar at diﬀerent time points (a). After 30
days, colonies were formed in N-MASCs (b) and C-MASCs culture, but not in L-MASCs culture, as represented in the histogram (c). Data
are presented as mean ± standard deviation. ∗P<. 05 versus L-MASCs.
Moreover, evaluating the migration ability by scratch
assay (Figure 6(e)), we established that L-MASCs grown in
a medium conditioned by Huh7 displayed, with respect to
L-MASCs grown in non-CM or HepG2-CM, a signiﬁcantly
increased migration speed (Figures 6(e)–6(f)).
Altogether, these results showed that MASCs obtained
from noncirrhotic and nonneoplastic livers, when cultured
in the presence of a medium conditioned by tumor cells,
acquired properties speciﬁc of tumor associated ﬁbroblasts.
4. Discussion
Similarly to what we have previously shown for other normal
humantissues[24,25],itispossibletoisolateapopulationof
multipotent adult stem cells (MASCs) from either cirrhotic
or neoplastic specimens. Although the in vivo counterpart
o fM A S C si ss t i l lu n d e ﬁ n e d[ 24, 25], this cell type shares
some features with activated hepatic stellate cells [34, 35].
Recently, it has been hypothesized that hepatic stellate cells
are indeed progenitor cells, expressing Oct-4 and markers
of all the three germ layers, which are able to give rise, in
vitro, to endothelial cells and hepatocytes [34, 35]. Moreover,
a fate-mapping study showed that stellate cells could become
oval cells when activated in liver injury, and that these cells
participate in ductular proliferation [36]. All these evidences
point to the presence of mesenchymal, widely multipotent
cells in adult tissues, which can take part to regenerative as
well as inﬂammatory and neoplastic processes [37].
In this paper, we documented for the ﬁrst time that
MASCs isolated from HCC and cirrhotic samples have the
main characteristics of TAFs, as opposed to those isolated
from noncirrhotic, nonneoplastic livers. This result is in line
with what has been shown for other solid tumors such as
breast, pancreas, and prostate cancer [12, 17]. The ways in
which TAFs could act on tumor growth are numerous. TAFs
are contractile cells, associated with blood vessels, and able
to produce growth factors (HGF, TGF-β, EGF, bFGF, and
IGF), cytokines, chemokines, and enzymes, to degrade the
extracellular matrix, and to act as immunomodulating cells,
thus increasing tumor growth by creating a microenviron-
ment suitable for this process [12, 17, 18]. Moreover, the
presenceof TAFs in the tumor is associated withan increased
metastatic potential and, in general, with a poor prognosis
[12].
Interestingly, the TAF aberrant growth properties, dis-
played by N- and C-MASCs, could persist despite extensive
culture; this feature has also been described for other tumors
and has been ascribed to epigenetic mechanisms [38, 39].
Since many of the neoplastic livers were surgical treated
after transarterial chemoembolization (TACE), it could be
postulatedthatTACEcouldhavealteredthegrowthbehavior
of MASCs, but (1) C-MASCs, with similar characteristics
to those obtained from neoplastic livers, were obtained
also from cirrhotic not neoplastic livers that were never
exposed to chemoembolization; (2) the eﬀect that medium
conditioned by hepatocellular carcinoma cell lines exerts
on normal liver cell lines showed that factors released by
neoplastic cells can inﬂuence the in vitro behavior of L-
MASCs, never exposed to chemoembolization.
Importantly, the fact that TAF-like cells could be isolated
from cirrhotic, nonneoplastic livers, suggests that cirrhosis is
characterizedbya microenvironment possibly favoring HCC
onset. In fact, most cases of hepatocellular carcinoma are
linked to the presence of cirrhosis [5, 6]. Therefore, there
is a great interest in understanding the mechanisms that
determine the appearance of neoplastic transformation in
cirrhoticliversinordertopreventthedevelopmentofcancer,
identify useful markers for early diagnosis, and introduce
novel therapeutic approaches. For example, several studies
have highlighted the key role played in these processes byInternational Journal of Hepatology 11
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Figure 5: L-MASCs cultured in the presence of tumor-conditioned medium (CM) acquire an activated phenotype. (a–u) Protein expression
of TAF-markers. L-MASCs cultured in non-CM (a, d, g, j, m, p, s), in HepG2-CM (b, e, h, k, n, q, t), and in Huh7-CM (c, f, i, l, o, r, u) were
assessed for the expression of vimentin (green ﬂuorescence, (a–c)), nestin (green ﬂuorescence, (d–f)), cytokeratines (green ﬂuorescence, (g–
i)), desmin (green ﬂuorescence, (j–l)), smooth muscle actin (green ﬂuorescence, (m–o)), tenascin-C (p–r)), and VEGF (green ﬂuorescence,
(s–u)). Nuclei are depicted by the blue ﬂuorescence of DAPI staining. Scale bar = 30μm (a–o), 20μm (p–u). (v) mRNA expression of TAF
markers. Representative RT-PCR evaluating the expression of THBS1, FSP1, FAP, ACTA2, and GAPDH in L-MASCs cultured in non-CM,
HepG2-CM, and Huh7-CM, respectively. HeLa was utilized as positive control (+).
the ﬁbroblast activating protein (FAP) [40]. This protein,
involved in the production/degradation of the extracellular
matrix [41], is expressed in cirrhotic livers by hepatic stellate
cells and myoﬁbroblasts [42]. Interestingly, FAP is also
expressed by TAFs and was found to play a key role in
the biology of diﬀerent tumors, including hepatocellular
carcinoma [43].
However, many questions remain unanswered. For
example, it would be extremely interesting to understand
the mechanism through which chronic proinﬂammatory
insults give rise to TAFs and whether it is possible to
detect etiology-based diﬀerences (e.g., viral infections versus
autoimmune versus toxicity). In our casistic, C-MASCs
isolated from alcohol-related (n = 3) and from virus-
related cirrhosis (n = 15) showed similar characteristics in
terms of surface immunophenotype and aberrant growth
properties. However, an in depth comparison of the diﬀerent
etiology would require a larger sampling. Similarly, it would
be important to understand whether TAFs obtained from
neoplastic but not cirrhotic livers are diﬀerent from the TAFs
obtained from cirrhotic and neoplastic livers. Preliminary
results obtained in our laboratory indicate that TAFs can be
obtained from HCC arose in noncirrhotic livers (n = 2, data
not shown), but it is necessary to increase the sample size to
assess possible signiﬁcant diﬀerences.
Finally, we have shown that although L-MASCs do not
possess TAF features, when cultured in the presence of
medium conditioned by tumor cell lines, they acquired
aberrant growth properties and the ability to produce
speciﬁc TAF markers [11, 12, 18]. Regarding the origin
of TAFs, four possible sources were envisioned [12, 18,
22]: epithelial-mesenchymal transition of the neoplastic
cells (excluded by the absence of genetic alterations within
the TAFs) [12], recruitment and activation of resident
ﬁbroblasts, recruitment of circulating/bone marrow-derived
mesenchymal stem cells, and recruitment of resident stem
cells. Recent studies have shown that mesenchymal stem cells
derived from bone marrow can give rise to TAFs [18, 20, 44].
Here we show that TAFs could arise from a population of
resident primitive cells with mesenchymal features. In any
case, the possibility that TAFs could derive from resident
or circulating mesenchymal stem cells opens a new scenario
for understanding the biology of cancer and to identify new
therapeutic targets. In fact, although the mechanisms that
regulate TAFs and their accumulation in tumor sites are not
yet clariﬁed, it seems clear that blocking the activation of
TAFs and their continuous communication with the cancer
cells could, in conjunction with chemotherapy regimens,
limit tumor progression and metastasis [9, 22, 45]. One
possible advantage in targeting the stroma includes the fact
that TAFs are not as genetically unstable as malignant cells,
making it less likely the onset of resistance to chemotherapy
drugs [21, 46]. Some attempts have already been done in
this direction. For example, intratumoral injection of an
FAP-activatedprotoxinproducedsigniﬁcantlysisandgrowth
inhibition of human breast and prostate cancer xenografts
with minimal toxicity to the host animal [45], while genetic
deletion and pharmacologic inhibition of FAP inhibited
tumor growth in both mouse models of lung and colon
cancer [47]. Accordingly, it has been constructed an oral
DNA vaccine targeting FAP able to suppress, in vaccinated
animals, primary tumor cell growth and metastasis of
multidrug-resistantmurinecolonandbreastcarcinoma[48].
The hypothesis that liver TAFs could originate from a
population of primitive mesenchymal stem cells supports
the notion that tumor-supporting stroma derived from a
hierarchical cellular system in which rare stem cells, such as
multipotent adult stem cells (MASCs), would be responsible
forformingandinstructingalltheelementsofthesupportive
microenvironment. The fact that TAFs can originate from a
resident population of multipotent adult stem cells with a
mesenchymal immunophenotype could explain some of the
crucial TAF features. In fact, MASCs are able to diﬀerentiate
into many stromal cell types and, as previously shown, theirInternational Journal of Hepatology 13
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and HepG2-CM, respectively (f).
gene expression proﬁle is characterized by a molecular signa-
ture consisting of a module of overexpressing genes involved
in extracellular matrix remodeling, in immunomodulation,
and in the production of growth factors and cytokines [24].
Selectively targeting this population, blocking its activation
ordiﬀerentiationintoTAFsmaybeaninnovativetherapeutic
approach that could act upstream with respect to the pro-
posed therapies. Last, the possibility to have in vitro human
models in which it is possible to induce TAF formation
starting from normal multipotent adult stem cells could help
in identifying key molecular events that could become target
of novel interventions.
5. Conclusions
In conclusion, the two main ﬁndings emerged from this
work are as follows. (1) Cirrhotic livers, not yet neoplastic,
already possess a population of multipotent adult stem
cells with TAF properties; these multipotent cells can be
propagated in culture without reversion of the activated
phenotype, and thus they represent a possible tool for
understanding the biological mechanisms underlying the
neoplastic transformation in cirrhotic livers. (2) Multipotent
adult stem cells isolated from healthy livers can acquire a
TAF phenotype when grown in conditioned medium from14 International Journal of Hepatology
tumor cell lines, suggesting that multipotent cells residing in
the liver may represent a population that, once recruited and
conditioned by tumor cells, contributes to the formation of
stroma and, in turn, to the progression of tumor.
Both the depicted models can play in the future a role
in understanding biological phenomena related to hepato-
carcinogenesis and in identifying novel therapies aimed at
interfering with the interaction between stroma and cancer
cells.
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